Despite major advances in diagnostics and translational science, one of the most persistent bottlenecks in research remains surprisingly basic: access to high-quality biospecimens. Across the research ecosystem, valuable samples sit in disconnected institutional repositories—often difficult for researchers to find, access, or use efficiently. The result is a fragmented system that slows biomarker validation, increases development costs, and ultimately delays progress for patients.
While discussions about innovation frequently focus on new technologies, the reality is that the ability to efficiently access the right specimens at the right time is just as critical to advancing science.
Impact Versus Inventory
Many institutions measure the success of their biobanking programs by the size of their collections. But large inventories do not necessarily translate into scientific impact. Samples without standardized metadata, consistent quality controls, or clear alignment with research demand often remain unused.
In practice, the most effective biobanks are not those with the largest collections—they are the ones that move the right samples into the hands of the right researchers quickly and efficiently. Success should be measured not by how many samples are stored, but by how they are used to enable research and discovery.
In other words, the best-run biobank is not necessarily the fullest one. It is the one with the greatest research impact.
How Fragmentation Slows Research
One of the biggest barriers researchers face today is fragmentation across biobanks and repositories. Samples are distributed across hundreds of institutions, each operating under its own governance structures, data standards, and access procedures.
Researchers can spend months identifying and validating specimen sources. This process might involve contacting multiple institutions individually, navigating varying consent policies, and coordinating multiple regulatory approvals. Even when suitable samples exist, simply discovering where they are and determining whether they are usable can be a time-consuming process.
These inefficiencies create real-world delays in diagnostic development. The time required to assemble appropriate cohorts can significantly extend research timelines and increase development costs.
The challenge is rarely a single bottleneck. Instead, progress is slowed by a combination of operational barriers and institutional silos that together create friction across the research ecosystem.
Why Biobanks Became Siloed
The current landscape did not emerge intentionally. Most biobanks were created independently by hospitals, academic institutions, diagnostic laboratories, or pharmaceutical companies to support their own research priorities.
Over time, these collections evolved with different consent frameworks, metadata standards, storage protocols and governance policies.
At the same time, concerns around privacy, intellectual property, and institutional liability reinforced a culture of ownership rather than collaboration.
These factors have produced a system where valuable specimens exist, but are often difficult to locate, access, or integrate into broader research initiatives.
The Case for Interoperable Biobank Networks
A more efficient model would allow independent biobanks to remain autonomous while participating in a shared ecosystem that enables specimen discovery and responsible collaboration.
In an interoperable biobank network, institutions could maintain control of their collections while participating in systems that allow researchers to identify relevant samples across multiple repositories simultaneously, and in time for an actual research project. Shared metadata standards and coordinated access frameworks would dramatically improve the discoverability and usability of specimens.
Such systems could also help reduce waste. Every year, significant volumes of potentially valuable biological material are discarded simply because no mechanism exists to match those specimens with researchers who could use them.
While the concept of interoperable biobank networks is compelling, implementing such systems requires coordination across multiple operational and regulatory domains. Advances in digital infrastructure and data standards are making these collaborative models increasingly achievable.
Responsible Data Sharing and Ethical Stewardship
Any move toward greater interoperability must be grounded in strong ethical and governance frameworks. Biospecimens represent contributions from patients who expect their samples to advance scientific knowledge while protecting their privacy.
Responsible data sharing relies on explicit consent, strict de-identification of patient information, clear governance and oversight structures, controlled access models and compliance with regulatory frameworks.
When implemented responsibly, these safeguards allow organizations to expand the impact of biospecimens while maintaining trust and protecting patient interests.
Expanding Innovation Through Collaboration
Improved collaboration across biobanks could significantly accelerate several areas of biomedical innovation.
For example, digital pathology and AI-driven analytics increasingly rely on large collections of well-annotated biological data. Even when physical samples are depleted, digital images, sequencing data, and associated metadata can continue to support future research.
By creating systems that make specimens and their associated data more easily accessible, the research ecosystem can gain greater value from existing collections and reduce redundant specimen collection.
Ultimately, the goal is not simply to store biospecimens—it is to enable discoveries that improve patient care.
From Ownership to Stewardship
Achieving this vision will require a shift in how organizations think about biobanking. Rather than viewing specimens primarily as assets, the future of biobanking lies in stewardship—ensuring that samples are used responsibly and effectively to advance research.
Patients contribute biological samples with the expectation that they will drive progress. Ensuring those contributions have the greatest possible scientific impact requires greater collaboration, improved interoperability, and a shared commitment to responsible specimen stewardship.
About the Author
Dr. Zoran Gatalica
Dr. Gatalica is Medical Director at Reference Medicine and a physician, pathologist, and consultant with extensive experience in biotechnology and academia. His expertise includes molecular and genomic profiling, precision medicine laboratory strategy, lab management, regulatory compliance, and translational research.
